Achillion Pharma (ACHN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Achillion Reports 2014 Fourth Quarter and Year-End Financial Results
March 5, 2015 6:05 AM ESTNEW HAVEN, Conn., March 5, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today reported financial results for the three and twelve months ended December 31, 2014.
For the three months ended December 31, 2014, the Company reported a net loss of $21.6 million, compared to a net loss of $13.4 million in the three months ended December 31, 2013. For the full year ended December 31, 2014, the Company's net loss was $69.0 million, or $0.70 per share, compared to a net loss of $58.9 million for the year ended December 31, 2013, or $0.63 per share. Cash, cash equivalents, marketable securities, and interest and subscriptions receivable at December... More
Achillion Reports 2014 Fourth Quarter and Year-End Financial Results
March 5, 2015 6:05 AM ESTNEW HAVEN, Conn., March 5, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today reported financial results for the three and twelve months ended December 31, 2014.
For the three months ended December 31, 2014, the Company reported a net loss of $21.6 million, compared to a net loss of $13.4 million in the three months ended December 31, 2013. For the full year ended December 31, 2014, the Company's net loss was $69.0 million, or $0.70 per share, compared to a net loss of $58.9 million for the year ended December 31, 2013, or $0.63 per share. Cash, cash equivalents, marketable securities, and interest and subscriptions receivable at December... More
